A new sensitive enzyme-linked immunosorbent assay (Elisa) for alemtuzumab determination: Development, validation and application

International Journal of Immunopathology and Pharmacology

Volumn 20, Issue 2, 2007, Pages 363-371

  Montagna, M ^a   Avanzini, M A ^a   Visai, L ^b   Locatelli, F ^a   Montillo, M ^c   Morra, E ^c   Regazzi, Mario B ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Alemtuzumab; Autoimmune diseases; CD52 antigen; CLL; ELISA

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B; BETAMETHASONE; CHLORPHENIRAMINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HYDROCORTISONE; IMMUNOGLOBULIN G; LEVOFLOXACIN; PAPAIN; PARACETAMOL; POLYCLONAL ANTIBODY; VINCRISTINE;

ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NONHUMAN; PRIORITY JOURNAL; RABBIT; SERUM; VALIDATION STUDY;

EID: 34547111027     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200702000217     Document Type: Article

References (27)

1. Xia M.Q., G. Hale, M.R. Lifely, M.A. Ferguson, D. Cambell, L. Packman and H. Waldmann. 1993. Structure of the CAMPATH-1 antigen, a glycosylp hosphatidylisonitol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochemistry 293:633.
2. Treumann A., M.R. Lifely, P. Schneider and M.A. Ferguson. 1995. Primary structure of CD52. J. Biol. Chem. 270:6088.
3. Kirchoff C. and S. Schroter. 2001. New insights into the origin, structure and role of CD52: a major component of the mammalian sperm glycocalyx. Cells Tissues Organs 168:93.
4. Hale G. 2001. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3:137.
5. Rowan W., J. Tite, P. Topley and S.J. Brett. 1998. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95:427.
6. Elsner J., R. Hochstetter, K. Spiekrmann and A. Kapp. 1996. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 88:4684.
7. Taylor M.L., P.W. Noble, B. White, R. Wise, M.C. Liu and B.S. Bochner. 2000. Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. Clin. Immunol. 94:33.
8. Gilleece M.H. and T.M. Dexter. 1993. Effect of CAMPATH antibody on human hematopoietic progenitors in vitro. Blood 82:807.
9. Riechmann L., M. Clark, H. Waldmann and G. Winter. 1998. Reshaping human antibodies for therapy. Nature 332:323.
10. ndSymposium on: Monoclonal Antibody Therapies for Hematological Malignances and Autoimmune Diseases. Modena (Italy).
11. Hale G. 1995. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1:175.
12. Tadaki D.K., H. Xu, L. Graham, D.H. Harlan and A.D. Kirk. 2001. CAMPATH-1H resistant monocytes are deficient in indirect but capable of direct alloantigen presentation. Program and Abstracts of Transplant 2001: The joint American Transplant meeting. Chicago (Illinois). Abstract 345.
13. Hale G., M.Q. Xia, H.P. Tighe, M.J. Dyer and H. Waldmann. 1990. The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118.
14. Ferrajoli A., S.M. O'Brien, J.E. Cortes, D.A. Thomas, S. Falderal, R. Kurzrock, S. Lerner, D.P. Kontoyiannis and M.J. Keating. 2003. Phase II Study of Alemtuzumab in Chronic Lymphoproliferative Disorders. Cancer 98:773.
15. O'Brien S.M., H.M. Kantarjian, D.A. Thomas, J. Cortes, W.G. Wierda, C.A. Roller, A. Ferrajoli, S. Lerner, M. Albitar and M.J. Keating. 2003. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98:2657.
16. Montillo M., T. Schinkoethe and T. Elter. 2005. Eradication of minimal residual disease with alemtuzumab in b-cell chronic lymphocytic leukemia (b-cll) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest. 23:488.
17. Khouri I.F., M. Albitar, R.M. Saliba, C. Ippoliti, Y.C. Ma, M.J. Kaeting and R.E. Champlin. 2004. Low-dose Alemtuzumab (Campath®) in myeloablative allogeneic stem cell transplantation for CD52 positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant. 33:833.
18. Regazzi M., I. Iacona and M. Montagna. 2003. Clinical pharmacology of the monoclonal antibodies Rituximab and Campath-1H. Haematologica 88:39.
19. Hale G., P. Jacobs, L. Wood, W.E. Fibbe, R. Barque, N. Novitzky, C. Toit, L. Abrahams, V. Thomas, D. Bunjes, C. Duncker, N. Wiesneth, D. Selleslag, M. Hidajat, M. Starobinski, P. Bird and H. Waldmann. 2000. CD52 antibodies for prevention of graft-versus-host disease and graft blood rejection following transplantation of allogenic peripheral blood stem cells. Bone Marrow Transplant. 26:69.
20. Hale G. and H. Waldmann. 1996. Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant. 17:305.
21. Hale G., S. Cobbolb and H. Waldmann. 1988. T cell depletion with CAMPATH-1 in allogenic bone marrow transplantation. Transplantation 45:753.
22. Hale G., P. Rebello, L.R. Brettman, C. Fegan, B. Kennedy, E. Kimby, M. Leach, J. Lundin, H. Mellstedt, P. Moreton, A.C. Rawstron, H. Waldmann, A. Osterborg and P. Hillmen. 2004. Blood concentrations of Alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104:948.
23. Rebello P. and G. Hale. 2002. Pharmacokinetics of CAMPATH-1H: assay development and validation. J. Immunol. Methods 260:285.
24. Jilani I., M. Keating, F.J. Giles, S. O'Brien, H.M. Kantarjian and M. Albitar. 2004. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk. Res. 28:1255.
25. Harlow E. and D. Lane. 1988. Using Antibodies: A Laboratory Manual. CSHL Press, New York, USA.
26. Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680.
27. th Annual Congress of the European Hematology Association (EHA). Genève, Switzerland.